Qiagen N.V. Common Shares (QGEN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- Trading 27% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 11.2% — below-average profitability
- Revenue growing at 6% annually
Qiagen N.V. Common Shares (QGEN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NYSE , with a market capitalisation of $7.6 billion . Key value metrics: P/E ratio 18.0, P/B ratio 2.02, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Qiagen N.V. Common Shares — Fundamental Analysis Summary
Qiagen N.V. Common Shares (QGEN) is currently trading 27% above its Graham Number of $27.71, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 18.0x.
On financial health, QGEN shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 11.2% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.44.
StockPik's composite Value Score for QGEN is 96/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
QGEN reports a high gross margin of 62.2% (sector average: 40.1%) and a strong operating margin of 22.3%.
QGEN shows revenue growing at 6% year-over-year, with earnings growing at 408%.
QGEN pays a modest dividend yield of 0.7%.